

Alamar Biosciences establishes commercial presence in Asia Pacific region

07 December 2024 | News

With first ARGO HT installation at Hong Kong Center for Neurodegenerative Diseases



Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, has announced its commercial presence in the Asia Pacific (APAC) region with the installation of the ARGO HT System, an advanced ultra-sensitive proteomics platform, at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND).

The ARGO HT System along with the NULISA Platform are designed to revolutionise biomarker discovery by enabling researchers to detect and quantify proteins at unprecedented levels of sensitivity and accuracy.

"Expansion of the ARGO HT installed base to the APAC region represents a significant step forward in our vision to bring transformative proteomics solutions to researchers worldwide," said Dr Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences.

Prof. Nancy Ip, the Director of Hong Kong Center for Neurodegenerative Diseases (HKCeND), added, "The integration of the NULISA Technology enabled by the ARGO HT System into our research infrastructure is a game-changer. This technology will allow us to explore the proteomic underpinnings of neurodegenerative diseases in ways that were previously unimaginable."

The partnership with HKCeND will focus on unlocking new insights into the molecular mechanisms of neurodegenerative diseases such as Alzheimer's disease, and Parkinson's disease. The ARGO HT System and NULISA Platform deployments will empower HKCeND's researchers to identify novel biomarkers, accelerate drug development, and improve early detection and personalised treatment strategies for patients.